C3L-04391
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 70.20123203
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.650
- MYC_TARGETS_V1+0.490
- MTORC1_SIGNALING+0.460
- TNFA_SIGNALING_VIA_NFKB+0.430
- UNFOLDED_PROTEIN_RESPONSE+0.430
- PROTEIN_SECRETION+0.420
- G2M_CHECKPOINT+0.390
- UV_RESPONSE_DN+0.390
- ANGIOGENESIS+0.380
- INTERFERON_ALPHA_RESPONSE+0.380
Top 10 suppressed
- BILE_ACID_METABOLISM-0.220
- KRAS_SIGNALING_DN-0.080
- PEROXISOME-0.020
- ESTROGEN_RESPONSE_EARLY+0.010
- FATTY_ACID_METABOLISM+0.020
- ESTROGEN_RESPONSE_LATE+0.060
- ADIPOGENESIS+0.070
- IL6_JAK_STAT3_SIGNALING+0.070
- SPERMATOGENESIS+0.070
- DNA_REPAIR+0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934867 | — | — | 0.904 |
| 2 | SRR934963 | — | — | 0.904 |
| 3 | 2F14C141-CE43-4934-BEC9-769A181DB053 | — | — | 0.903 |
| 4 | C9EE359E-2F42-4D20-880D-FBF8B4953731 | — | — | 0.897 |
| 5 | TCGA-CV-7097-01A-11R-2016-07 | — | — | 0.893 |
| 6 | E317AD4C-E877-499A-B108-2F39A40D1682 | — | — | 0.890 |
| 7 | 443B59BB-0BFD-459A-896E-FA07AA6C3A45 | — | — | 0.890 |
| 8 | MNG1191 | — | — | 0.886 |
| 9 | 7E198F8E-BBAA-419D-8986-359C109FBE74 | — | — | 0.885 |
| 10 | TCGA-BH-A0DZ-01A-11R-A00Z-07 | — | C | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 47 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.650 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.460 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.430 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.380 | Inavolisib | — uncovered |
| APOPTOSIS | 0.370 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.250 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |